Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform
Prnewswire·2026-01-16 14:20
BELLEVUE, Wash., Jan. 16, 2026 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneer in oral T-cell immunotherapies for cancer, today announced the appointment of Sébastien Wieckowski, PhD, as Chief Scientific Officer (CSO). This appointment strategically strengthens Vaximm's leadership with deep, long-standing expertise in the company's core technology. Dr. Wieckowski brings multidisciplinary experience spanning immunology and advanced data science, a profile uniquely poised to integr ...